within Pharmacolibrary.Drugs.ATC.L;

model L04AD01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.006166666666666667,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.00396,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008666666666666666,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Ciclosporin (also known as cyclosporine) is a calcineurin inhibitor immunosuppressant primarily used to prevent organ transplant rejection and to treat autoimmune diseases such as rheumatoid arthritis and psoriasis. It is approved for use in many countries and remains an important drug in transplant medicine.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following oral administration; parameters are population means reported in published literature.</p><h4>References</h4><ol><li><p>Chryssafidis, P, et al., &amp; Macheras, P (2022). Re-writing Oral Pharmacokinetics Using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models. <i>Pharmaceutical research</i> 39(4) 691–701. DOI:<a href=&quot;https://doi.org/10.1007/s11095-022-03230-0&quot;>10.1007/s11095-022-03230-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35378697/&quot;>https://pubmed.ncbi.nlm.nih.gov/35378697</a></p></li><li><p>Fruit, D, et al., &amp; Prémaud, A (2013). Ciclosporin population pharmacokinetics and Bayesian estimation in thoracic transplant recipients. <i>Clinical pharmacokinetics</i> 52(4) 277–288. DOI:<a href=&quot;https://doi.org/10.1007/s40262-013-0037-x&quot;>10.1007/s40262-013-0037-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23400901/&quot;>https://pubmed.ncbi.nlm.nih.gov/23400901</a></p></li><li><p>Cibulskyte, D, et al., &amp; Mortensen, J (2006). The pharmacokinetics and acute renal effects of oral microemulsion ciclosporin A in normal pigs. <i>International immunopharmacology</i> 6(4) 627–634. DOI:<a href=&quot;https://doi.org/10.1016/j.intimp.2005.09.013&quot;>10.1016/j.intimp.2005.09.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16504926/&quot;>https://pubmed.ncbi.nlm.nih.gov/16504926</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AD01;
